Patent ID: 11957716
Assignee: IMMATICS BIOTECHNOLOGIES GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 20:
21. A method of treating a patient who has cancer, wherein the cancer cells present a peptide consisting of the amino acid sequence VFLLLPYPRF (SEQ ID NO: 31), comprising administering tothe patient an effective number of the activated T lymphocytes of claim 19,
wherein the cancer is selected from the group consisting of acute myeloid leukemia, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, glioblastoma, gastric cancer, gastro-esophageal junction cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, urinary bladder carcinoma, and uterine endometrial cancer.